Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

Shares of NuVasive, Inc. (NASDAQ:NUVA - Get Rating) have earned a consensus rating of "Hold" from the fifteen research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $61.75.

A number of analysts recently commented on the stock. Canaccord Genuity Group boosted their price objective on shares of NuVasive from $50.00 to $55.00 in a report on Friday, August 5th. Morgan Stanley dropped their price target on shares of NuVasive from $62.00 to $54.00 and set an "equal weight" rating for the company in a research report on Friday, July 15th. Piper Sandler dropped their price target on shares of NuVasive from $80.00 to $60.00 and set an "overweight" rating for the company in a research report on Thursday, August 4th. Finally, Truist Financial dropped their price target on shares of NuVasive to $63.00 in a research report on Friday, July 22nd.Hedge Funds Weigh In On NuVasive

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Point72 Hong Kong Ltd raised its position in shares of NuVasive by 28.3% in the first quarter. Point72 Hong Kong Ltd now owns 1,347 shares of the medical device company's stock valued at $76,000 after purchasing an additional 297 shares during the period. Strs Ohio bought a new position in shares of NuVasive in the second quarter valued at approximately $73,000. Captrust Financial Advisors raised its position in shares of NuVasive by 85.7% in the first quarter. Captrust Financial Advisors now owns 2,108 shares of the medical device company's stock valued at $120,000 after purchasing an additional 973 shares during the period. PNC Financial Services Group Inc. raised its position in shares of NuVasive by 76.4% in the first quarter. PNC Financial Services Group Inc. now owns 2,175 shares of the medical device company's stock valued at $123,000 after purchasing an additional 942 shares during the period. Finally, Acadian Asset Management LLC bought a new position in shares of NuVasive in the first quarter valued at approximately $189,000. NuVasive Price Performance

Shares of NASDAQ:NUVA opened at $51.30 on Wednesday. The company's fifty day moving average price is $50.94 and its 200 day moving average price is $52.75. NuVasive has a 12 month low of $45.45 and a 12 month high of $64.43. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.17 and a quick ratio of 0.70. The firm has a market capitalization of $2.67 billion, a P/E ratio of -64.13, a P/E/G ratio of 2.05 and a beta of 1.14. NuVasive Company Profile (Get Rating)

NuVasive, Inc, a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment.Recommended StoriesGet a free copy of the StockNews.com research report on NuVasive (NUVA)Are 3M, Honeywell, GE Buys After Quarterly Reports?CVS and Walgreens Show Why Investment Objectives Matter Is Sofi Financial Stock Finally Ready to Pay Off for Investors?This Defense Stock Has Bullish Fundamentals AND TechnicalsAre Medtronic And Intuitive Surgical Poised For Big Growth?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider NuVasive, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NuVasive wasn't on the list.

While NuVasive currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

What investors can learn from studying the past, as well as offering some ideas about asset classes with future potential.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.